Q&A: Is the medical community on the brink of a cure for Huntington's disease?
Huntington's disease is a fatal, hereditary neurological disorder mostly striking people between the ages of 30 and 50.
Sep 30, 2025
0
20
Therapeutics: News and Research on RNAi Therapeutics
MeSH tree: E02.095.301.250
Running interference: Scientists block viral RNA, aiming to cure hepatitis B
Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of drugs, its luck may be running out.
Jul 23, 2025
0
73
Six-month injection lowers blood pressure in patients not helped by standard drugs
Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that giving people with high blood pressure an injection every six months can lead to a meaningful, sustained ...
May 28, 2025
0
32
FDA approves new drug to treat heart conditions
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people.
Mar 24, 2025
0
29
Promising biomarker could decode cause of aggressive breast cancer in women of color
Triple-negative breast cancer (TNBC) is an aggressive breast cancer. It spreads quickly and has few treatment options. It is also serious because of its rate of recurrence.
Dec 20, 2024
0
85
Vutrisiran offers a new lifeline to patients with progressive heart condition
Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented ...
Aug 30, 2024
0
25
Promising results for hyperlipidemia treatment reduce risk of cardiovascular events
Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia—elevations of triglycerides and cholesterol.
May 28, 2024
0
51
Study finds single dose of zilebesiran safely and effectively lowers blood pressure for six months
A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 ...
Nov 13, 2023
0
41
Patisiran can preserve functional capacity in transthyretin amyloidosis, according to study
For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published in ...
Oct 27, 2023
0
34
Iron regulation offers new treatment hope for incurable blood cancer
A landmark discovery linking iron regulation to a rare blood cancer has led to clinical trials of a potential new treatment for patients with the incurable disease.
Apr 4, 2023
0
68
